Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EIF4A1 | P60842 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11289917 | 0.90 | CYP2D6 (0.46) | MAPTCYP2D6KCNH2ADORA2AADORA1 | |
| SCHEMBL8553165 | 0.88 | CYP2D6 (0.46) | EIF4A1MAPTCYP2D6KCNH2ADORA2A | |
| SCHEMBL10390768 | 0.85 | EIF4A1 (0.49) | EIF4A1HTTKDM4ELMNAEPRS1 | |
| SCHEMBL11669235 | 0.85 | AURKA (0.55) | — | |
| SCHEMBL8556340 | 0.85 | KCNH2 (0.45) | EIF4A1MAPTCYP2D6KCNH2ADORA2A | |
| SCHEMBL7221372 | 0.85 | CYP2D6 (0.46) | EIF4A1MAPTCYP2D6KCNH2ADORA2A | |
| SCHEMBL31118733 | 0.84 | EIF4A1 (0.48) | EIF4A1MAPTHTTALDH1A1KDM4E | |
| SCHEMBL16832498 | 0.84 | KDM4E (0.46) | EIF4A1MAPTMEN1KMT2AKDM4E | |
| SCHEMBL10758255 | 0.82 | PDE10A (0.64) | EIF4A1HTTSMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL7122718 | 0.80 | CYP3A4 (0.43) | MAPTCYP2D6KCNH2ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0026894-B1 | PROCESS FOR THE PREPARATION OF ERYTHRO-ALPHA-2-PIPERIDYL-2,8-BIS (TRIFLUOROMETHYL)-4-QUINOLINE METHANOL | BASF Aktiengesellschaft (DE) | 1983-03-30 | — | — | EP | claimed |
| US-4327215-A | Preparation of erythio-αpiperid-2-yl-2,8-bis-trifluoro-methyl)-quinolin-4-yl-methanol | BASF AKTIENGESELLSCHAFT (DE) | 1982-04-27 | — | — | US | claimed |
| EP-0026894-A1 | Process for the preparation of erythro-alpha-2-piperidyl-2,8-bis (trifluoromethyl)-4-quinoline methanol | BASF Aktiengesellschaft (DE) | 1981-04-15 | — | — | EP | claimed |
| US-20210308120-A1 | Use of Amitriptyline for Blocking Brain Hemichannels and Method for Potentiating its Effect in Vivo | THERANEXUS (FR) | 2021-10-07 | — | — | US | disclosed |
| EP-3322412-B1 | USE OF AMITRIPTYLINE FOR BLOCKING BRAIN HEMICHANNELS AND METHOD FOR POTENTIATING ITS EFFECT IN VIVO | THERANEXUS (FR) | 2021-04-07 | — | — | EP | disclosed |
| US-20180207147-A1 | USE OF AMITRIPTYLINE FOR BLOCKING BRAIN HEMICHANNELS AND METHOD FOR POTENTIATING ITS EFFECT IN VIVO | THERANEXUS (FR) | 2018-07-26 | — | — | US | disclosed |
| EP-3322412-A1 | USE OF AMITRIPTYLINE FOR BLOCKING BRAIN HEMICHANNELS AND METHOD FOR POTENTIATING ITS EFFECT IN VIVO | Theranexus (FR) | 2018-05-23 | — | — | EP | disclosed |
| WO-2017009472-A1 | USE OF AMITRIPTYLINE FOR BLOCKING BRAIN HEMICHANNELS AND METHOD FOR POTENTIATING ITS EFFECT IN VIVO | THERANEXUS (FR) | 2017-01-19 | — | — | WO | disclosed |
| US-8716265-B2 | 4-quinolinemethanols as anti-malarial agents | JENRIN DISCOVERY, INC. (US) | 2014-05-06 | — | — | US | disclosed |
| US-8716265-B2 | 4-quinolinemethanols as anti-malarial agents | JENRIN DISCOVERY, INC. (US) | 2014-05-06 | — | — | US | disclosed |
| US-20120178717-A1 | 4-QUINOLINEMETHANOLS AS ANTI-MALARIAL AGENTS | JENRIN DISCOVERY (US) | 2012-07-12 | — | — | US | disclosed |
| EP-0975345-A1 | (-)-MEFLOQUINE TO BLOCK PURINERGIC RECEPTORS AND TO TREAT MOVEMENT OR NEURODEGENERATIVE DISORDERS | Cerebrus Pharmaceuticals Limited (GB) | 2000-02-02 | — | — | EP | disclosed |
| WO-1999026627-A1 | (-)-MEFLOQUINE TO BLOCK PURINERGIC RECEPTORS AND TO TREAT MOVEMENT OR NEURODEGENERATIVE DISORDERS | CEREBRUS LIMITED (GB) | 1999-06-03 | — | — | WO | disclosed |
| US-5175297-A | METHYL-QUINOLINE DERIVATIVES AS MEFLOQUIN INTERMEDIATES AND PROCESS FOR PREPARATION THEREOF | ALKALOIDA VEGYESZETI GYAR (HU) | 1992-12-29 | — | — | US | disclosed |
| US-5166354-A | QUINOLINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | ALKALOIDA VEGYESZETI GYAR (HU) | 1992-11-24 | — | — | US | disclosed |
| EP-0026894-B1 | PROCESS FOR THE PREPARATION OF ERYTHRO-ALPHA-2-PIPERIDYL-2,8-BIS (TRIFLUOROMETHYL)-4-QUINOLINE METHANOL | BASF Aktiengesellschaft (DE) | 1983-03-30 | — | — | EP | disclosed |
| US-4327215-A | Preparation of erythio-αpiperid-2-yl-2,8-bis-trifluoro-methyl)-quinolin-4-yl-methanol | BASF AKTIENGESELLSCHAFT (DE) | 1982-04-27 | — | — | US | disclosed |
| US-4327215-A | Preparation of erythio-αpiperid-2-yl-2,8-bis-trifluoro-methyl)-quinolin-4-yl-methanol | BASF AKTIENGESELLSCHAFT (DE) | 1982-04-27 | — | — | US | disclosed |
| EP-0026894-A1 | Process for the preparation of erythro-alpha-2-piperidyl-2,8-bis (trifluoromethyl)-4-quinoline methanol | BASF Aktiengesellschaft (DE) | 1981-04-15 | — | — | EP | disclosed |
| EP-0026894-A1 | Process for the preparation of erythro-alpha-2-piperidyl-2,8-bis (trifluoromethyl)-4-quinoline methanol | BASF Aktiengesellschaft (DE) | 1981-04-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178717-A1 | 4-QUINOLINEMETHANOLS AS ANTI-MALARIAL AGENTS | CYP51A1, SQLE, NQO2 | EIF4A1 2708/4885MAPT 484/4885CYP2D6 276/4885 |
| US-20180207147-A1 | USE OF AMITRIPTYLINE FOR BLOCKING BRAIN HEMICHANNELS AND METHOD FOR POTENTIATING ITS EFFECT IN VIVO | GAP43, GJB2, HCN3 | EIF4A1 2735/4885MAPT 1650/4885CYP2D6 401/4885 |
| US-20210308120-A1 | Use of Amitriptyline for Blocking Brain Hemichannels and Method for Potentiating its Effect in Vivo | GAP43, GJB2, HCN3 | EIF4A1 2735/4885MAPT 1650/4885CYP2D6 401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.